Shukra Pharma shares hit 5% upper circuit after reporting robust results in Q3 FY26

Synopsis: Shukra Pharmaceuticals Limited reports 566.61% YoY revenue growth and a 759.07% YoY surge in net profit in Q3 FY26 results.

This Small-cap Pharma Stock, engaged in manufacturing affordable generic tablets, capsules, and injectables for infections, pain, and allergies across India and global markets, hit a 5 percent upper circuit after the company reported December quarterly results with 566.61 percent Revenue Growth and 759.07 percent Profit growth in Q3  FY26.

With a market capitalization of Rs. 1,770.35 crores, the shares of Shukra Pharmaceuticals Limited hit a 5 percent upper circuit of Rs. 40.43 per share on Thursday, up from its previous closing price of Rs. 38.51 per share.

Q3 FY26 Result

Coming into the quarterly results of Shukra Pharmaceuticals Limited, the company’s consolidated revenue from operations increased by 269.85 percent YOY, from Rs. 10.58 crore in Q3 FY25 to Rs. 39.13 crore in Q3 FY26, and grew by 566.61 percent QoQ from Rs. 5.87 crore in Q2 FY26.

In Q3 FY26, Shukra Pharmaceuticals Limited’s consolidated net profit increased by 544.30 percent YOY, reaching Rs. 20.36 crore compared to Rs. 3.16 crore during the same period last year. As compared to Q2 FY26, the net profit has increased by 759.07 percent, from Rs. 2.37 crore. The basic earnings per share increased by 840 percent and stood at Rs. 0.47 as against Rs. 0.05 recorded in the previous quarter in the financial year, FY2026.

Shukra Pharmaceuticals Limited reported a revenue of Rs. 32.59 crore and a profit of Rs. 9.58 crore for FY25. In terms of return ratios, the company’s ROCE and ROE stand at 18.17 percent and 20.39 percent, respectively. Shukra Pharmaceuticals Limited has an earnings per share (EPS) of Rs. 0.27, and its debt-to-equity ratio is 0.06x.

Manufacturing Capacity

Shukra Pharmaceuticals Limited has strong large-scale manufacturing capacity, producing up to 720 million tablets and 90 million capsules annually in oral solid dosage forms. In addition, the company operates advanced injectable manufacturing facilities with the capacity to produce 40 million ampoules and 50 million vials per year, supporting high-volume and reliable pharmaceutical production.

Global Presence

Shukra Pharmaceuticals Limited has an expanding global presence across Africa, Southeast Asia, and the CIS region. The company exports to key African markets, including Nigeria, Kenya, Uganda, and Ghana, as well as Vietnam, Myanmar, and Cambodia in Southeast Asia, and Turkmenistan in the CIS region, demonstrating its commitment to international healthcare access.

Shukra Pharmaceuticals Limited was started in 1993 as Relish Pharmaceuticals. The company is based in Ahmedabad and manufactures affordable generic medicines. It focuses on making tablets, capsules, and injectable drugs like ampoules and vials. The company produces these for markets in India, CIS countries, Africa, and Southeast Asia. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Shukra Pharma shares hit 5% upper circuit after reporting robust results in Q3 FY26 appeared first on Trade Brains.